Earnings Feed
Sign Up
Home/Filings/4/0001178913-23-001111
4//SEC Filing

Cohen Neil Harris 4

Accession 0001178913-23-001111

CIK 0001534248other
View on SEC.govCompany Profile

Filed

Mar 22, 8:00 PM ET

Accepted

Mar 23, 7:35 AM ET

Size

14.0 KB

Accession

0001178913-23-001111

Insider Transaction Report

Form 4
Period: 2023-03-16
Chemomab Therapeutics Ltd.CMMB
Cohen Neil Harris
Directorinterim CEO
Transactions
  • Award

    Option to Purchase American Depositary Shares

    2023-03-16+6,875→ 6,875 total
    Exercise: $1.62Exp: 2033-03-21→ American Depositary Shares (6,875 underlying)
  • Award

    Option to Purchase American Depositary Shares

    2022-03-07+6,820→ 6,820 total
    Exercise: $3.53Exp: 2032-03-07→ American Depositary Shares (6,820 underlying)
  • Award

    Option to Purchase American Depositary Shares

    2021-04-19+11,884→ 11,884 total
    Exercise: $27.26Exp: 2031-04-19→ American Depositary Shares (11,884 underlying)
  • Award

    Option to Purchase American Depositary Shares

    2021-03-16+688→ 688 total
    Exercise: $13.17Exp: 2030-07-15→ American Depositary Shares (688 underlying)
Holdings

  • American Depositary Shares

    10,000
Footnotes (6)
  • [F1]Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
  • [F2]No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
  • [F3]These options were granted as per the annual grant of options to directors. Those options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.
  • [F4]These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors
  • [F5]These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
  • [F6]These options vest and become exercisable as follows: 1/3 vested on July 16, 2021, and the remaining options vest on a quarterly basis for the following eight quarters, subject to the Reporting Person's continued service.

Documents

1 file

Issuer

Chemomab Therapeutics Ltd.

CIK 0001534248

→
Entity typeother

Related Parties

1
  • filerCIK 0001840006

Filing Metadata

Form type
4
Filed
Mar 22, 8:00 PM ET
Accepted
Mar 23, 7:35 AM ET
Size
14.0 KB
View on SEC.gov